The global biological data visualization market was valued at USD 459.91 million in 2021 and it is predicted to surpass around USD 1.44 billion by 2030 with a CAGR of 13.52% from 2022 to 2030.
Report Highlights
The growing research in genomics and proteomics is one of the major market drivers. Major companies in the market are focusing on strategic initiatives such as new product launches, mergers and acquisitions, and technological collaborations, to increase their share in the biological data visualization market. For instance, in August 2021, DNAnexus, Inc. announced that the standards of the biomedical informatics platform outperformed the online security policy objectives outlined in the U.S. Government's recent executive order. This helped build confidence in the product among NGS end-users and assisted in managing large biomedical information with high security.
The life-science researchers and practitioners rely on visualization techniques for solving a wide range of challenges in understanding and interpreting biological information. Rapid advancements in raw computing power and graphics processing power make visualization of biological information easier on commodity desktop platforms. Besides, the increase in the adoption Of Next-Generation Sequencing (NGS) techniques and other biological data-acquisition approaches, which generate new types and sets of data, necessitates the demand for visualization tools among researchers and scientists.
For instance, Spain has become an attractive and competitive market for NGS data analysis. In September 2020, the Government of Spain allocated USD 29.5 million for precision and genomic medicine, and data science. This investment aims to enhance the capacity of the regional health system and use scientific knowledge as a tool to embrace economic competitiveness by contributing to innovation. The total funds allocated for 2 years (2020-22) is USD 89.33 million. The segment of investment includes genomic medicine, big data health, predictive medicine, advanced and personalized therapy, and precision medicine training.
The COVID-19 pandemic resulted in increased usage of sequencing information analysis platform plays a crucial role in the detection and tracing of the virus and support the growth of the biological data visualization market. Various sequencing surveillance platforms and solutions are being deployed for the effective diagnosis of infection. Furthermore, key stakeholders are undertaking various strategic initiatives, such as collaborations and licensing for collaborative efforts, to combat the disease. For instance, in February 2021, the Canadian government invested USD 53 million to implement a multilayered approach to the diagnosis of COVID-19. The Canadian government will utilize genome sequencing and analysis technologies to achieve desired outcomes.
Technological advancements in analytical and business intelligence solutions coupled with rapid growth in big data and the rise in the need for faster decision-making are a few other drivers boosting the demand for visualization tools in the bioinformatics field. The sheer amount of high-dimensional biological information needs machine learning and advanced data visualization approaches so that it can be easily understandable by human experts.
On the other hand, the biological data visualization market is fragmented in nature with a substantial number of companies ranging from large global players to small mid-sized local or regional players.
Scope of The Report
Report Coverage | Details |
Market Size in 2021 | USD 459.91 million |
Revenue Forecast by 2030 | USD 1.44 billion |
Growth rate from 2022 to 2030 | CAGR of 13.52% |
Base Year | 2021 |
Forecast Period | 2022 to 2030 |
Segmentation | Technique, application, platform, end-use, region |
Companies Covered |
Thermo Fisher Scientific, Inc.; 3M; Tableau Software, LLC; QIAGEN; ZEISS International; Oxford Instruments; Olympus Corporation; General Electric Company; Agilent Technologies Inc.; Clarivate |
Technique Insights
The sequencing segment is projected to have a considerable market share of 36.06% in 2021. Genomic analysis is expected to witness significant growth in the near future, due to the expansion of Next-generation Sequencing (NGS) technologies. The introduction of novel NGS platforms by companies, such as Illumina, Inc. and Thermo Fisher Scientific, Inc, as well as the declining cost of sequencing, facilitates the generation of a large amount of genomic information that requires biological data visualization tools to be analyzed.
Furthermore, the introduction of workflow management systems solutions such as Galaxy and Chipster drive demand for technological advancements in information storage and management. Demand for technologically advanced infrastructure to monitor the flow of data analysis process from information generation to preliminary analysis to higher-level analysis has increased. Constantly undergoing developments in information analysis tools for obtaining effective results is anticipated to drive the market over the forecast period.
The magnetic resonance imaging segment is estimated to have the fastest CAGR in the market. Several MRI-based tools, such as BrainVoyager, have been developed for the extraction, analysis, and visualization of brain models from MRI data. Similarly, software tools, such as Cardiac Image Modeller developed by the University of Auckland, New Zealand, are specific for cardiac image processing and analysis.
Similarly, in September 2022, Qynapse Inc. collaborated with researchers from the University of Miami Miller School of Medicine to study the impact of the SARS-Cov-2 virus on vascular contributions to dementia and cognitive impairment through AI. The subjects’ MRI, neuropsychological, clinical, and biological data is likely to be collected. Hence, the integration of MRI techniques and AI for information analysis is expected to support the growth of the biological data visualization market.
Application Insights
The application of visualization software for the visualization of cell and organism images accounted for a substantial revenue share of 38.86% in 2021. The advanced microscopy technology and workflows rapidly deliver millions of images at cellular and sub-cellular levels. In addition, when the cells are labeled with dyes or antibodies facilitates the detection of proteins even at a single-cell level. With these advancements, cellular phenotypes can be also quantified. The generation of 3D microscopic images further drives segment growth.
Genomic analysis is projected to witness the fastest growth during the forecasted period. The study of genomes has become digital to a larger extent by the emergence of sequencing technology and its ability to determine genomic sequences at nucleotide resolution. The recent innovations in sequencing technology provide a unique capacity for information generation. Improvements in technology are expected to influence market growth in the near future. For instance, in October 2021, a group of researchers developed CoolBox, a toolkit for visual analysis of genomics information. The toolkit is user-friendly and compatible with the Python ecosystem. CoolBox is anticipated to enable researchers to produce visualization plots and assess the information in a flexible way.
Platform Insights
The windows segment accounted for a significant revenue share of 60.15% in 2021. Windows is an extensively used operating system among all other operating systems. Currently, around 90% of computers and laptops possess Microsoft Windows 10 globally. This operating system is widely available globally and has longer life as compared to other platforms. It has the largest software library in the world. The main advantage of using Windows is that it is a highly compatible operating system with all kinds of software used for information visualization.
Although Linux is an open source operating system when compared to MAC OS and Windows. This operating system can be easily used by users, thus increasing its usability. However, as compared to Windows, this operating system possesses a complex version structure. Due to the open-source nature of Linux, numerous Linux-based operating systems, known as distros, are introduced, which impose difficulty in choosing the appropriate version.
End-use Insights
Academic research dominated the market and accounted for the largest revenue share of 60.77% in 2021. Additionally, funds provided by the government for promoting research in academic institutes, which use NGS platforms, further increase the usage of information analysis tools. For instance, in November 2019, the National Institutes of Health (NIH) provided funding of USD 29.5 million to academic centers for a new human genome reference program. The Washington University, the European Bioinformatics Institute, and the University of California received USD 12.5 million to establish a reference center for the human genome.
Furthermore, the pharmaceutical and biotechnological companies segment is projected to be the end-user with the fastest growth rate. The ongoing partnerships among research entities with companies for the development of visualization tools and incorporation of these tools are expected to drive revenue generation considerably. For instance, in January 2022, BGI Americas Corporation announced to collaborate with Gencove to offer comprehensive sequencing solutions to customers. The partnership includes sequencing service by BGI through DNBSEQ sequencing technology with an analysis platform by Gencove. The purpose of this partnership is to offer genomic information to the players in personalized medicines and bio-sustainability.
Regional Insights
North America dominated the biological data visualization market with the highest share of 44.19% in 2021. Its market growth can be attributed to the developed bioinformatics framework, the increase in the adoption of several computational methods, and the widespread application of advanced sequencing technologies. A large number of academic and research organizations are involved in investigating various molecular biology approaches by applying bioinformatics tools, which is expected to propel the use of information visualization tools over the coming years.
The growth of the market in the Asia Pacific is also driven by the development of public and private organizations that focus on bioinformatics, computational technologies, and big data. HKUST Big Data Institute is one such example that provides a strong leadership role in Data Science and Big Data research in Hong Kong as well as across the world by conducting educational programs and research projects in Data Science and Big Data. For instance, in September 2022, HKUST announced to collaborate with the Applied Science and Technology Research Institute (ASTRI) for research and promote the sharing of technology including big data analysis and AI, in the area of pharmaceutical R&D, Fintech, and traditional Chinese medicine (TCM) service systems.
Key Players
Market Segmentation
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Biological Data Visualization Market
5.1. COVID-19 Landscape: Biological Data Visualization Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Biological Data Visualization Market, By Technique
8.1. Biological Data Visualization Market, by Technique, 2022-2030
8.1.1. Microscopy
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Magnetic resonance imaging
8.1.2.1. Market Revenue and Forecast (2017-2030)
8.1.3. Sequencing
8.1.3.1. Market Revenue and Forecast (2017-2030)
8.1.4. X-ray Crystallography
8.1.4.1. Market Revenue and Forecast (2017-2030)
8.1.5. Others
8.1.5.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Biological Data Visualization Market, By Application
9.1. Biological Data Visualization Market, by Application, 2022-2030
9.1.1. Cell And Organism Imaging
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Structural Biology And Molecular Modeling
9.1.2.1. Market Revenue and Forecast (2017-2030)
9.1.3. Genomic Analysis
9.1.3.1. Market Revenue and Forecast (2017-2030)
9.1.4. Alignments, phylogeny, And Evolution
9.1.4.1. Market Revenue and Forecast (2017-2030)
9.1.5. Systems Biology
9.1.5.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Biological Data Visualization Market, By Platform
10.1. Biological Data Visualization Market, by Platform, 2022-2030
10.1.1. Windows
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2. Mac OS
10.1.2.1. Market Revenue and Forecast (2017-2030)
10.1.3. Linux
10.1.3.1. Market Revenue and Forecast (2017-2030)
10.1.4. Others
10.1.4.1. Market Revenue and Forecast (2017-2030)
Chapter 11. Global Biological Data Visualization Market, By End-use
11.1. Biological Data Visualization Market, by End-use, 2022-2030
11.1.1. Academic Research
11.1.1.1. Market Revenue and Forecast (2017-2030)
11.1.2. Pharma & Biotech Companies
11.1.2.1. Market Revenue and Forecast (2017-2030)
11.1.3. Hospitals & Clinics
11.1.3.1. Market Revenue and Forecast (2017-2030)
11.1.4. Others
11.1.4.1. Market Revenue and Forecast (2017-2030)
Chapter 12. Global Biological Data Visualization Market, Regional Estimates and Trend Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Technique (2017-2030)
12.1.2. Market Revenue and Forecast, by Application (2017-2030)
12.1.3. Market Revenue and Forecast, by Platform (2017-2030)
12.1.4. Market Revenue and Forecast, by End-use (2017-2030)
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Technique (2017-2030)
12.1.5.2. Market Revenue and Forecast, by Application (2017-2030)
12.1.5.3. Market Revenue and Forecast, by Platform (2017-2030)
12.1.5.4. Market Revenue and Forecast, by End-use (2017-2030)
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Technique (2017-2030)
12.1.6.2. Market Revenue and Forecast, by Application (2017-2030)
12.1.6.3. Market Revenue and Forecast, by Platform (2017-2030)
12.1.6.4. Market Revenue and Forecast, by End-use (2017-2030)
12.2. Europe
12.2.1. Market Revenue and Forecast, by Technique (2017-2030)
12.2.2. Market Revenue and Forecast, by Application (2017-2030)
12.2.3. Market Revenue and Forecast, by Platform (2017-2030)
12.2.4. Market Revenue and Forecast, by End-use (2017-2030)
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Technique (2017-2030)
12.2.5.2. Market Revenue and Forecast, by Application (2017-2030)
12.2.5.3. Market Revenue and Forecast, by Platform (2017-2030)
12.2.5.4. Market Revenue and Forecast, by End-use (2017-2030)
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Technique (2017-2030)
12.2.6.2. Market Revenue and Forecast, by Application (2017-2030)
12.2.6.3. Market Revenue and Forecast, by Platform (2017-2030)
12.2.6.4. Market Revenue and Forecast, by End-use (2017-2030)
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Technique (2017-2030)
12.2.7.2. Market Revenue and Forecast, by Application (2017-2030)
12.2.7.3. Market Revenue and Forecast, by Platform (2017-2030)
12.2.7.4. Market Revenue and Forecast, by End-use (2017-2030)
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Technique (2017-2030)
12.2.8.2. Market Revenue and Forecast, by Application (2017-2030)
12.2.8.3. Market Revenue and Forecast, by Platform (2017-2030)
12.2.8.4. Market Revenue and Forecast, by End-use (2017-2030)
12.3. APAC
12.3.1. Market Revenue and Forecast, by Technique (2017-2030)
12.3.2. Market Revenue and Forecast, by Application (2017-2030)
12.3.3. Market Revenue and Forecast, by Platform (2017-2030)
12.3.4. Market Revenue and Forecast, by End-use (2017-2030)
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Technique (2017-2030)
12.3.5.2. Market Revenue and Forecast, by Application (2017-2030)
12.3.5.3. Market Revenue and Forecast, by Platform (2017-2030)
12.3.5.4. Market Revenue and Forecast, by End-use (2017-2030)
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Technique (2017-2030)
12.3.6.2. Market Revenue and Forecast, by Application (2017-2030)
12.3.6.3. Market Revenue and Forecast, by Platform (2017-2030)
12.3.6.4. Market Revenue and Forecast, by End-use (2017-2030)
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Technique (2017-2030)
12.3.7.2. Market Revenue and Forecast, by Application (2017-2030)
12.3.7.3. Market Revenue and Forecast, by Platform (2017-2030)
12.3.7.4. Market Revenue and Forecast, by End-use (2017-2030)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Technique (2017-2030)
12.3.8.2. Market Revenue and Forecast, by Application (2017-2030)
12.3.8.3. Market Revenue and Forecast, by Platform (2017-2030)
12.3.8.4. Market Revenue and Forecast, by End-use (2017-2030)
12.4. MEA
12.4.1. Market Revenue and Forecast, by Technique (2017-2030)
12.4.2. Market Revenue and Forecast, by Application (2017-2030)
12.4.3. Market Revenue and Forecast, by Platform (2017-2030)
12.4.4. Market Revenue and Forecast, by End-use (2017-2030)
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Technique (2017-2030)
12.4.5.2. Market Revenue and Forecast, by Application (2017-2030)
12.4.5.3. Market Revenue and Forecast, by Platform (2017-2030)
12.4.5.4. Market Revenue and Forecast, by End-use (2017-2030)
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Technique (2017-2030)
12.4.6.2. Market Revenue and Forecast, by Application (2017-2030)
12.4.6.3. Market Revenue and Forecast, by Platform (2017-2030)
12.4.6.4. Market Revenue and Forecast, by End-use (2017-2030)
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Technique (2017-2030)
12.4.7.2. Market Revenue and Forecast, by Application (2017-2030)
12.4.7.3. Market Revenue and Forecast, by Platform (2017-2030)
12.4.7.4. Market Revenue and Forecast, by End-use (2017-2030)
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Technique (2017-2030)
12.4.8.2. Market Revenue and Forecast, by Application (2017-2030)
12.4.8.3. Market Revenue and Forecast, by Platform (2017-2030)
12.4.8.4. Market Revenue and Forecast, by End-use (2017-2030)
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Technique (2017-2030)
12.5.2. Market Revenue and Forecast, by Application (2017-2030)
12.5.3. Market Revenue and Forecast, by Platform (2017-2030)
12.5.4. Market Revenue and Forecast, by End-use (2017-2030)
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Technique (2017-2030)
12.5.5.2. Market Revenue and Forecast, by Application (2017-2030)
12.5.5.3. Market Revenue and Forecast, by Platform (2017-2030)
12.5.5.4. Market Revenue and Forecast, by End-use (2017-2030)
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Technique (2017-2030)
12.5.6.2. Market Revenue and Forecast, by Application (2017-2030)
12.5.6.3. Market Revenue and Forecast, by Platform (2017-2030)
12.5.6.4. Market Revenue and Forecast, by End-use (2017-2030)
Chapter 13. Company Profiles
13.1. Thermo Fisher Scientific, Inc.
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. 3M
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Tableau Software, LLC
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. QIAGEN
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. ZEISS International
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Oxford Instruments
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Olympus Corporation
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. General Electric Company
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Agilent Technologies Inc.
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Clarivate
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
Chapter 14. Research Methodology
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
Chapter 15. Appendix
15.1. About Us
15.2. Glossary of Terms